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Abstract: Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members
expressed on the surface of several leukocytes and tissue cells and has a key function
in detecting pathogen and danger-associated molecular patterns. The role of TLR4 in
the pathophysiology of several age-related diseases is also well recognized, such as
prostate cancer (PCa). TLR4 polymorphisms have been related to PCa risk, but the
relationship between TLR4 genotypes and aggressive PCa risk has not been
evaluated by any systematic reviews.
Methods: We performed a systematic review and meta-analysis of candidate-gene and
genome-wide association studies analyzing this relationship and included only white
population. Considering appropriate criteria, only nine studies were analyzed in the
meta-analysis, including 3,937 aggressive PCa and 7,382 controls.
Results: Using random effects model, no significant association was found in the ten
TLR4 SNPs reported by at least four included studies under any inheritance model
(rs2737191, rs1927914, rs10759932, rs1927911, rs11536879, rs2149356, rs4986790,
rs11536889, rs7873784, and rs1554973). Pooled estimates from another ten TLR4
SNPs reported by three studies also showed no significant association (rs10759930,
rs10116253, rs11536869, rs5030717, rs4986791, rs11536897, rs1927906, rs913930,
rs1927905, and rs7045953). Meta-regression revealed that study type was not a
significant source of between-study heterogeneity.
Conclusions: TLR4 polymorphisms were not significantly associated with the risk of
aggressive PCa.
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Abstract 
Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members expressed on the surface 
of several leukocytes and tissue cells and has a key function in detecting pathogen and danger-associated 
molecular patterns. The role of TLR4 in the pathophysiology of several age-related diseases is also well 
recognized, such as prostate cancer (PCa). TLR4 polymorphisms have been related to PCa risk, but the 
relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by any systematic 
reviews.   
 
Methods: We performed a systematic review and meta-analysis of candidate-gene and genome-wide 
association studies analyzing this relationship and included only white population. Considering appropriate 
criteria, only nine studies were analyzed in the meta-analysis, including 3,937 aggressive PCa and 7,382 
controls.  
 
Results: Using random effects model, no significant association was found in the ten TLR4 SNPs reported 
by at least four included studies under any inheritance model (rs2737191, rs1927914, rs10759932, 
rs1927911, rs11536879, rs2149356, rs4986790, rs11536889, rs7873784, and rs1554973). Pooled estimates 
from another ten TLR4 SNPs reported by three studies also showed no significant association (rs10759930, 
rs10116253, rs11536869, rs5030717, rs4986791, rs11536897, rs1927906, rs913930, rs1927905, and 
rs7045953). Meta-regression revealed that study type was not a significant source of between-study 
heterogeneity. 
 
Conclusions: TLR4 polymorphisms were not significantly associated with the risk of aggressive PCa.  
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Introduction  
Prostate cancer (PCa) is the most common malignancy since 1984, the most frequently diagnosed 
cancer, and the second leading cause of cancer-related deaths in 2013 among men in the USA [1]. The risk 
of PCa is related to family history, race, and genetic factors. Several other causes have been associated 
with PCa pathogenesis, including infectious agents, chronic non-infectious inflammatory diseases, diet, 
environmental carcinogens, imbalance of sex hormone, obesity, and urine reflux [2-4]. Chronic 
inflammation has been linked to the pathogenesis of PCa in both epidemiologic studies and molecular 
pathology investigations [5,6]. In particular, several studies have suggested that sexually transmitted 
infections may be a risk factor for PCa through causing inflammation, even though not all the studies are 
consistent [7,8]. Chronic inflammation seems to induce prostate carcinogenesis and also promote 
neoplastic progression [9]. Furthermore, several pathways linking inflammation and PCa have been 
identified: an intrinsic one driven by genetic events that cause neoplasia, and an extrinsic one driven by 
inflammatory conditions that predispose to cancer [9]. Among these, the eicosanoid pathway activated by 
cyclooxygenase 2 (COX-2) has been suggested to be involved in the pathogenesis of aggressive PCa by a 
recent study [10]. COX-2 was over-expressed in PCa tumors and the intensity of immunostaining was 
correlated with prostate tumor grade [11]. Despite the available evidence on the role of the inflammatory 
response in PCa onset and progression, the association between genetic variants of innate immune genes 
and the risk of aggressive PCa remains unclear.  
Toll-like receptor 4 (TLR4) is an important pathogen recognition receptor involved in detection of  
lipopolysaccharide (LPS) of Gram-negative bacteria and other exogenous or endogenous ligands [12]. The 
TLR4 encoding gene is located on chromosome 9q32-q33. Through nuclear factor kappa B (NF-κB), 
TLR4 initiates the production of pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6 and tumor 
necrosis factor- (TNF-) [13]. TLR4 also mediates signaling related to tumor cell invasion, survival, and 
metastasis in various cancers [14,15]. Its activity and function seems to be modulated by genetic variations, 
principally single nucleotide polymorphisms (SNPs). Mice with deficiency or mutation of TLR4 had a 
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weaker inflammatory immune response to viral, bacterial [16,17], and protozoal [18] infections than that of 
wild-type mice. Therefore, variations in TLR4 gene may modify the signaling of the immune response, 
which in turn may have effects on the pathogenesis of PCa.  
 Three recent meta-analyses have explored the association between TLR4 SNPs and PCa [19-21]. They 
all reported non-significant findings after stratification by ethnicity. However, these studies focused their 
attention on overall PCa and did not contain genome-wide association studies (GWASs). In addition, they 
did not analyze the association between TLR4 SNPs and the aggressive type of PCa. Thus, we conducted a 
systematic review and meta-analysis of all genetic epidemiologic association studies that have evaluated 
the relationship between TLR4 polymorphisms and risk of aggressive PCa. Both candidate-gene studies and 
GWASs were included. The primary research questions are: (1) is there an association between TLR4 SNPs 
and risk of aggressive PCa and if so, what is the size of the relationship? (2) what is the validity of the 
evidence of association between TLR4 polymorphisms and risk of aggressive PCa?   
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Materials and Methods 
Ethics Statement 
 The execution of each individual study was previously approved by the respective institution. This 
systematic review was performed at the study level without access to individual-level data, and therefore, 
institutional review board approval was not necessary. Informed consent was obtained from each 
participant before the start of each individual study. 
Study Selection 
The study was performed using pre-specified research objectives, search strategy, study eligibility 
criteria, methods of data extraction, and statistical analyses. Relevant studies were identified by searching 
the MEDLINE (http://gateway.ovid.com/), EMBASE (http://www.embase.com), Science Citation Index 
(http://science.thomsonreuters.com/cgi-bin/jrnlst/jlsearch.cgi?PC=K), and Online Mendelian Inheritance in 
Man (http://www.ncbi.nlm.nih.gov/omim) databases for all genetic association studies published before 
February 2013, using combinations of the search terms “toll-like receptor 4,” OR “toll-like receptor 4 
gene,” OR “TLR,” OR “TLR gene,” OR “TLR4,” OR “TLR4 gene,”  AND “prostate cancer,” OR 
“prostatic neoplasms.” GWASs were searched using combinations of the search terms “genome-wide 
association study,” OR “GWAS,” AND “prostate cancer,” OR “prostatic neoplasms.” In addition, we 
manually searched the reference lists from reviews and original articles to retrieve other papers relevant to 
the topic. Where there was overlap in the study populations of published papers, only the largest study was 
included. No language restriction was placed on the literature search strategies. Unpublished findings were 
not identified.  
Exposure Measures 
The main exposure variables were TLR4 genotypes as measured in blood DNA samples from men in 
the respective studies. This meta-analysis summarized TLR4 SNPs which were reported by at least three 
included studies. Because many TLR4 SNPs were explored by two studies only, and the respective sample 
sizes were small, these SNPs were not analyzed in this meta-analysis. 
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Outcome Measures 
The outcome measure was aggressive PCa as defined by Gleason score greater than or equal to seven, 
or TNM stage greater than or equal to T3b or any nodal involvement or any distant metastases. However, 
some included studies extended this definition. Controls for aggressive PCa are ideally men without 
aggressive PCa chosen from the population at risk, although some studies selected controls from men 
without screening for occult PCa (Table 1).   
Data Extraction 
Three of us (PH Weng, YL Huang, and YC Chen) independently reviewed each published paper and 
extracted relevant information examining the associations between TLR4 polymorphisms and risk of 
aggressive PCa. Inter-observer differences, if any existed, were reconciled through group discussion. In 
order to pool data from different studies, we requested data from each study based on the definition for 
aggressive PCa in this meta-analysis, which may be slightly different from their original design. For 
GWASs that did not report detailed information of TLR4, we contacted the investigators to obtain data on 
advanced PCa counts and the corresponding TLR4 genotyping frequencies. To avoid population 
stratification, this meta-analysis was restricted to samples taken from European ancestry. We evaluated 
selection bias based on the extent to which controls are representative of the “person-time population” 
from which the cases were sampled, and the extent to which cases are a random sample of that latter 
population. 
Statistical Analyses 
Meta-analyses were performed for SNPs that were reported by at least three included studies. The 
pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between TLR4 genotypes 
and risk of aggressive PCa were calculated using random effects models. Random effects models are 
preferred to fixed effect models because of the differences in study designs and study populations [22]. To 
incorporate both within-study and between-study variability, we used DerSimonian and Laird’s [23] 
random effects models to pool the estimates of log OR from each individual study (unadjusted for 
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covariates). Between-study heterogeneity was quantified by using the I
2
 statistic [24,25], which indicates 
the proportion of variability across studies attributable to heterogeneity. Tests of heterogeneity were 
assessed by a χ2 statistic. To explore the inheritance mode for the effect of TLR4 polymorphisms, we 
evaluated the following genotype contrasts (where a and A denote minor and major alleles, respectively): 
(1) a/a and A/a combined versus A/A (dominant model); (2) a/a versus A/a and A/A combined (recessive 
model); (3) a/a versus A/A and A/a versus A/A (co-dominant model); (4) the increment of one minor allele 
(additive model). The Hardy-Weinberg equilibrium (HWE) was assessed via χ2 test. We did not perform 
haplotype analysis because none of the previous studies performed haplotype analysis specific for these 
SNPs. Because most GWASs did not adjust for covariates, this meta-analysis reported unadjusted pooled 
results.  
 
To evaluate the presence of publication bias, we examined the funnel plot, by plotting the reciprocal of 
the standard error of log OR versus the log OR, for symmetry. The Egger linear regression test was also 
performed to assess funnel plot’s asymmetry [26]. Random effects meta-regression was performed under 
dominant model to explore possible sources of between-study heterogeneity. Study type (candidate-gene 
studies vs. GWASs) was the pre-specified covariate. We did not perform stratification analysis according 
to differences in control and case selection, because such influences are complex and are usually not 
unidirectional. Because previous studies revealed high concordance rate across genotyping platforms [27], 
stratification analysis was not carried out according to this covariate. Analyses were performed with Stata 
version 11.0 software (Stata Corporation, College Station, TX, USA). All P values were two-sided. 
QUANTO program (http://hydra.usc.edu/gxe/) was used to evaluate statistical power of the association 
between TLR4 polymorphisms and aggressive PCa.  
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Results 
Characteristics of Association Studies 
Using the pre-specified search methodology we retrieved forty relevant publications (Figure 1). After 
excluding duplicates (n=10), seventeen studies were further excluded due to the following reasons: (1) not 
European ancestry (n=5), (2) partially overlapped populations (n=9), (3) lack of controls (n=1), and (4) 
GWAS which did not include TLR4 gene (n=2).  
We contacted the authors of the remaining 13 relevant studies for necessary details, and authors of 
three of the GWASs [28-30] didn’t respond and were thus excluded. One GWAS was excluded because it 
didn’t contain the information of PCa aggressiveness [31]. For studies composed of multiple cohorts (e.g., 
Lindstrom et al. [32] ), we tried to obtain data from each cohort and used the original study to represent 
each cohort (e. g., Chen et al. [33] for HPFS, Dunggan et al. [34] for CAPS, and Yeager et al. [35] for 
PLCO). For the CAPS study, the GWAS by Dunggan et al. [34] was selected instead of the candidate-gene 
study done by Zheng et al. [36] because the former was composed of aggressive PCa cases from Zheng’s 
study and evaluated more SNPs. In sum, nine studies were included for the meta-analysis. 
A total of 3,937 aggressive PCa cases and 7,382 controls were included in this work. Six studies were 
candidate-gene studies [33,37-41], and three of them were GWASs [34,35,42]. Six papers studied US 
populations [33,35,37-39], one studied a Swedish population [34], one studied the combination of UK and 
Australian population [42], and one studied an Italian population [40]. Details of the studies analyzed in 
this meta-analysis were summarized in Table 1, including first author, year of publication, type of study, 
ancestry, sample size, control selection, possible sources of selection bias, definition of PCa 
aggressiveness, genotyping methods and quality control. 
For the association between TLR4 SNPs and aggressive PCa, seven studies assessed rs4986790 
[33-35,37,39,40,42]; five studies investigated rs2149356 [33,34,37,39,41], rs11536889 [33,34,37,39,41], 
rs7873784 [33,34,37,39,41]; and four studies explored rs2737191[34,35,41,42] , rs1927914 [33,34,38,39], 
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rs10759932 [33,34,37,41], rs1927911 [33,34,38,39], rs11536879 [34,35,38,42], and rs1554973 
[34,35,41,42].  
Allele Frequencies of TLR4 SNPs 
Ten TLR4 SNPs had been evaluated by at least 4 included studies. The minor allele frequencies (MAF) 
between case and controls were shown in Table 2, along with the test for HWE in controls. Among them, 
three SNPs are located on 5’ untranslated region (UTR, rs2737191, rs1927914 and rs10759932), three are 
intronic SNPs (rs1927911, rs11536879, and rs2149356), one is non-synonymous exonic SNP (rs4986790), 
and three SNPs are located on 3’ UTR (rs11536889, rs7873784, and rs1554973). Another 10 TLR4 SNPs 
were reported by 3 studies, including one SNP located on the promoter region (rs10759930), one SNP 
located on 5’UTR (rs10116253), two intronic SNPs (rs11536869 and rs5030717), one non-synonymous 
exonic SNP (rs4986791), and five SNPs located on 3’ UTR (rs11536897, rs1927906, rs913930, rs1927905, 
and rs7045953). The locations of the explored SNPs (10 SNPs with ≧4 studies, 10 SNPs with 3 studies) 
are shown in Figure 2. rs2149356, rs4986790 and rs7873784 in Chen’s study and rs1927911 in Wang’s 
study were out of HWE (P = 0.01-0.03) but were kept in the analysis because the HWE tests were not 
significant after correction for multiple tests. 
Meta-Analysis 
Using random effects meta-analysis, the ten TLR4 SNPs (rs2737191, rs1927914, rs10759932, 
rs1927911, rs11536879, rs2149356, rs4986790, rs11536889, rs7873784, and rs1444973) were not 
associated with the risk of aggressive PCa regardless of the inheritance model used (Table 3, Figure 3). The 
meta-analysis was also performed for another ten SNPs which were reported by three included studies 
(rs10759930, rs10116253, rs11536869, rs5030717, rs4986791, rs11536897, rs1927906, rs913930, 
rs1927905, and rs7045953) (Table S1). None of the SNPs revealed significant association with aggressive 
PCa. This meta-analysis was reported according to the PRISMA checklist [43] (Table S2).  
Publication Bias  
Funnel plots were used to assess the relationship between the ten TLR4 SNPs and aggressive PCa 
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(Figure S1). Using the Egger linear regression test, possible publication bias was found among the 
included studies on rs1554973 (Egger test P = 0.06). For the other 9 SNPs, P values ranged from 0.2 to 
0.77.  
Meta-regression 
Random effects meta-regression was performed under dominant model. Different study type 
(candidate-gene studies vs. GWASs) was not a significant source of between-study heterogeneity (P value 
ranged from 0.15 to 0.79 for the ten TLR4 SNPs). 
Power Calculation 
For people of European ancestry, given a MAF of 0.15 and α of 0.05, this study had over 95% power 
to detect an OR of 1.20 for 3,937 cases and 7,382 controls.  
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Discussion 
Recently, some researchers hypothesized that PCa is the result of a chronic inflammatory process [44]. 
Proliferative inflammatory atrophy (PIA), proposed as a potential precursor to PCa, occurs frequently in 
the periphery of the prostate gland where PCa occurs [5]. PIA lesions seem to be the result of different 
conditions, including infections, chronic non-infectious inflammatory diseases, dietary carcinogens, 
physical trauma, imbalance of sex hormone and urine reflux [9].Chronic infections may contribute to PIA 
and lead to onset of PCa [45-47]. Several innate inflammatory pathways seem to be involved. Among these, 
TLR4 pathway plays a crucial role [48].  
TLR4 recognizes pathogen-associated molecular patterns, i.e. LPS [46]. Damage-associated molecular 
pattern molecules may also interact with TLR4, i.e. oxidized low-density lipoprotein (LDL) [49], one of 
the atherogenic lipoproteins associated with atherosclerosis [50] and insulin resistance [51,52]. Their 
interaction leads to the initiation of inflammatory response via NF-κB (Figure 4) [53]. TLR4 can also 
promote PCa development through releasing inflammatory mediators. Associations between TLR4 SNPs 
and PCa have been examined in several studies, though discordant data have been reported. However, the 
relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by any systematic 
reviews. Thus, we performed a systematic review and meta-analysis of candidate-gene studies and GWASs 
analyzing this relationship and restricted to samples taken from European ancestry.  
In the current meta-analysis, none of the examined TLR4 SNPs was significantly associated with risk of 
aggressive PCa under any inheritance model. No significant association was found between the TLR4 
SNPs (5’UTR: rs2737191, rs1927914 and rs10759932; intron: rs1927911, rs11536879, and rs2149356; 
exon: rs4986790; 3’UTR: rs11536889, rs7873784, and rs1554973) and risk of aggressive PCa in the 
pooled analysis. The non-significant findings may be attributable to (1) failure to adjust for the 
conventional risk factors of PCa, e.g. family history of PCa, (2) inability to assess the within-population 
heterogeneity or geographic variation, and (3) the studied TLR4 SNPs may be more closely related to 
non-aggressive PCa.  
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 Three recent meta-analyses evaluated the association between TLR4 SNPs and overall PCa. Jing et al. 
[19], including four candidate-gene studies [33,37,39,40], examined two TLR4 SNPs (rs4986790 and 
rs4986791) and found that rs4986790 showed a protective effect on overall PCa under co-dominant and 
recessive models. However, the effect was not statistically significant after stratification by ethnicity. 
Another work by Zhang et al. [20] examined six TLR4 SNPs (rs1927914, rs4986790, rs4986791, 
rs11536889, rs1927911, rs2149356) and did not find significant associations with overall PCa. The pooled 
estimates of Zhang et al. were derived from one Asian study [54] and four other populations of European 
ancestry [33,36,39,41], which might be confounded by population stratification. Zhu et al. [21] examined 
rs4986790 and rs4986791 and found no significant association with overall PCa in five populations of 
European ancestry [33,36,37,39,40]. In summary, our findings on aggressive PCa are consistent with the 
previous meta-analyses on overall PCa. Our study had several advantages over the previous meta-analyses: 
(1) this study additionally included GWASs, whereas previous meta-analyses included candidate-gene 
studies only [19-21] , (2) this study focused on aggressive PCa, which is more clinically relevant, (3) this 
study was restricted to populations of European ancestry to avoid population stratification, and (4) this 
study evaluated an additional 14 SNPs, which were not reported in the previous meta-analyses. 
 Previous candidate-gene studies and GWASs found inconsistent results for the association between 
TLR4 polymorphisms and PCa risk. This may be explained by different ethnicity, within-population 
heterogeneity, case and control selection, gene-gene interactions, and gene-environment interactions. 
Although most of the relevant medical centers were in the “catchment” area, Cheng and colleagues [37] 
used controls from medical centers, which differ from the source population in that not all men with 
potential PCa would go to these centers to be screened and diagnosed. 
 There were some limitations of this study. One of them is the possibility of publication bias. Though 
the funnel plots did not reveal obvious publication bias among most of TLR4 SNPs, the SNPs reported in 
this study were under the influence of publication bias because only SNPs explored in ≧3 studies were 
included. We were unable to include three other GWASs because the authors did not respond to our data 
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request [28-30]. After exclusion of men with African and Asian ancestry, there was little evidence that 
population stratification was a cause of confounding. Though the included studies were conducted 
separately in the United States, Sweden, Italy, UK and Australia, a prior theoretical calculation on genetic 
case-control studies showed that ignoring ethnicity among non-Hispanic U.S. Caucasians with ancestries 
from different European countries resulted in bias of less than 1% [55]. Last, the included studies used 
different genotyping approaches, which may be associated with different genotyping success rates and data 
quality. However, genotyping errors are expected to be small, and thus the resulting biases are likely to be 
small.  
 This study had some advantages. To the best of our knowledge, this is the first meta-analysis on TLR4 
polymorphisms and aggressive PCa, which shows more clinical relevance. All the included studies were 
reasonably well-designed epidemiological studies. Genotyping was carried out “blind” to the disease status, 
and assessment of aggressive PCa was carried out “blind” to the genotypes. This study had sufficient 
power (> 0.95) to detect a potential OR of aggressive PCa associated with a SNP of 1.20. This study 
presents the best available evidence on the relationship between TLR4 polymorphisms and risk of 
aggressive PCa. 
 In conclusion, this study found that none of the examined TLR4 SNPs were significantly associated 
with risk of aggressive PCa under any mode of inheritance. Control selection, different ancestry, small 
statistical power in some studies, publication bias, gene-gene and gene-environment interactions, different 
genotyping approaches, and issues of multiple tests may contribute to the inconsistent findings in previous 
studies. Meta-regression revealed that different study type (candidate-gene studies vs. GWASs) was not a 
significant source of between-study heterogeneity. Large-scale and well-designed studies using 
population-based controls and more studies in each ethnic group are needed to confirm our findings. 
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Table S1 Pooled estimated ORs and 95% CIs for the association of TLR4 SNPs in aggressive PCa 
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Figure S1 Funnel plot of TLR4 SNPs 
Funnel plot displays the publication bias for each study (indicated as one dot) exploring the relation 
between TLR4 SNPs and aggressive prostate cancer. SNPs reported by at least four studies were shown 
here 
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Figure legends 
 
Figure 1. Study selection flowchart 
Forty studies were reviewed after literature search. Among them, 31 studies were excluded due to 
duplication, race other than whites, and insufficient data. A total of 9 studies were included for 
meta-analysis. 
 
Figure 2. TLR4 SNPs evaluated in this meta-analysis 
This plot was generated by the Locusview program. The highlighted boxed SNPs were TLR4 
polymorphisms explored by at least four studies. The remaining SNPs were those reported by three studies, 
discussed in the supplemental data. 
 
Figure 3. Forest plot examines relationship between TLR4 SNPs and risk of aggressive prostate 
cancer 
Odds ratios and weights were demonstrated for each individual study and for the pooled analysis, assuming 
a dominant model. SNPs that were evaluated by at least 4 studies were shown here. 
 
Figure 4. The role of TLR4 in innate immunity 
TLR4 receptors are responsible for the recognition of bacterial lipopolysaccharide (LPS) monomers and 
partially oxidized LDL (oLDL) on innate immune cells. LPS monomers and oLDL bind to sites on the 
protein, CD14. CD14 promotes the binding of these ligands to the TLR4-MD-2 complex, which signals the 
activation of the nuclear factor kappa B (NF-B) pathway. NF-B products enter the nucleus and result in 
transcription followed by the production of cytokines and the activation of multiple inflammatory 
pathways. This figure was adapted from DeFranco et al. [48]. 
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Table 1. Characteristics of the study populations that evaluated the relationship between TLR4 polymorphisms and risk of prostate 
cancer  
 
Source,  
publication year 
(study year) 
Type of 
study 
Country/ 
ancestry 
Aggressive 
PCa/ 
control 
Control selection Comments about  
control 
selection 
Case selection Definition of 
aggressive 
prostate cancer  
Outcome 
assessment 
“blinded” to 
genotype 
Genotyping procedures Genotyping 
quality control 
Chen et al., 2005 
 
(1993-1995) 
 
Candidate 
gene 
U.S. / 
97% 
Caucasians 
 
260/ 
700 
Age- matched controls 
from prospective 
cohort 
PSA tested in controls  Incident PCa TNM stage T3b 
or T4 or N1 or 
M1 or death due 
to PCa or 
Gleason sum  7 
Yes MassARRAY system 
(SEQUENOM)** 
100% 
concordance,  
> 95% 
genotyping 
success 
Dunggan et al., 
2007 
 
(2001-2002) 
  
 
GWAS Sweden/ 
Not mentioned 
505/ 
507 
Age-matched 
population controls 
from the same 
geographical region 
74% response rate in 
cases, 52% in controls. 
No PSA tested in 
controls.  
PCa from 
cancer registry 
TNM stage T3 or 
T4 or N+ or M+ 
or grade III or 
Gleason sum > 7 
or PSA > 100 
ng/ml 
Yes MassARRAY system 
(SEQUENOM) ** 
>99 % 
concordance, 
>98% genotyping 
success 
Yeager et al., 2007  
 
(1993-2001) 
GWAS U.S. 
/White and 
non-hispanic 
1081/ 
1416 
Risk set sampling from 
a population-based 
randomized controlled 
trial 
PSA tested in controls  Incident PCa Gleason sum  7 
or stage  3 
Yes Illumina system  >99 % 
concordance, 
>99% 
genotyping 
success 
Cheng et al., 2007 
 
(2002-2004) 
Candidate 
gene 
U.S./ 
Caucasians  
417/ 
417 
From annual medical 
examinations at the 
same medical 
institutions of cases 
Hospital-based study. 
PSA tested in controls  
Incident PCa TNM stage  
T2c or Gleason 
sum  7 or PSA> 
10 ng/ml 
Yes Taqman  100% 
concordance, 
99.9% 
genotyping 
success 
Eeles et al., 2008 
 
(1993-2001) 
  
GWAS U.K., 
Australia/ 
Excluded self- 
reported 
“non-white” 
564/ 
1894 
Community-based 
randomized controlled 
trial/electoral rolls  
Controls to be 
frequency matched to 
the geographical 
distribution of the 
cases.  
PCa from 
cancer registry, 
urology clinic 
Gleason sum  7 Yes Stage 1: Illumina Infinium 
HumanHap550 array 
Stage 2: Taqman 
>97 % SNPs at 
a confidence 
score of  0.25, 
98.8 % 
concordance  
Breyer et al.,2009 
 
(2002-2008) 
Candidate- 
gene 
U.S./ 
Americans of 
Northern 
European 
decents 
441/ 
772 
Age-matched controls 
from a preventive 
screening 
Hospital-based. 
PSA tested in controls  
Incident PCa Gleason sum  7 Yes Illumina GoldenGate platform 
and Taqman 
99.7 % of 
genotyping 
success 
Wang et al., 2009 
 
(1992-2002) 
Candidate 
gene 
U.S./ 
White only 
77/ 
264 
Age- matched controls 
from a prospective 
cohort  
No PSA tested in 
controls   
Incident PCa TNM stage T3 or 
T4 or N1 or M1 
or death due to 
PCa or Gleason 
sum  7 
Not  
mentioned 
Taqman 93-99 % 
genotyping 
success 
Ballistreri et al., Candidate Italy/ 32/ Age-matched controls Hospital-based study.  Prevalent PCa Gleason sum  7 Yes RFLP-PCR Not mentioned 
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2010 
 
(NA) 
gene European 
ancestry 
125 in good health No clear description 
on control selection. 
No PSA tested in 
controls 
Shui et al., 2012 
 
(1982-2004) 
Candidate 
gene  
U.S./ White 560/ 
1287 
Risk set sampling from 
a prospective cohort, 
matched on age and 
smoking 
 
No PSA tested in 
controls 
Incident PCa TNM stage T3 or 
T4, M1 or N1 or 
death due to PCa 
or Gleason sum 
 7 
Yes Sequenom iPLEX 
matrix-assisted laser 
desorption/ionization time of 
flight (MALDI-TOF) mass 
spectrometry technology. 
100% 
concordance, 
 >95% 
genotyping 
success 
Abbreviations: PCa, prostate cancer; TNM, the tumor node metastases classification system; PSA, prostate specific antigen; GWAS, 
genome-wide association study; RLFP-PCR, restriction fragment length polymorphism-polymerase chain reaction 
All studies met the following criteria and they were not listed in the table: (1) clear description of laboratory methods, (2) genotyping identical 
for cases and controls, (3) genotyping blinded to case control status, and (4) specimen came from peripheral blood sample. 
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Table 2. Characteristics of included studies 
 
 
SNPs that were evaluated by at least 4 studies were shown here. Abbreviations: MAF, minor allele frequency; HWE, Hardy–Weinberg 
equilibrium; NA, not available. 
 
 
 
 rs2737191 
(A/G) 
 rs1927914 
(A/G) 
 rs10759932 
(T/C) 
 rs1927911 
(G/A) 
 rs11536879 
(A/G) 
 rs2149356 
(G/T) 
 rs4986790 
(A/G) 
 rs11536889 
(A/G) 
 rs7873784 
(G/C) 
 rs1554973 
(T/C) 
 MAF    
case/  
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
Chen     
et al.,2005 
NA NA  0.30/    
0.35 
0.15  0.14/ 
0.16 
0.09  0.25/ 
0.29 
0.43  NA NA  0.30/ 
0.34 
0.02  0.04/ 
0.05 
0.01  0.15/ 
0.14 
0.52  0.15/ 
0.18 
0.03  NA NA 
Dunggan  
et al.,2007 
0.27/ 
0.27 
0.46  0.33/  
0.34 
0.55  0.16/ 
0.15 
0.71  0.27/ 
0.26 
0.74  0.01/ 
0.01 
0.82  0.31/ 
0.32 
0.89  0.05/ 
0.06 
0.15  NA NA  0.11/ 
0.13 
0.99  0.19/ 
0.21 
0.45 
Yeager   
et al.,2007  
0.28/ 
0.29 
0.88  0.32/ 
0.32 
0.94  NA NA  NA NA  0.04/ 
0.04 
0.83  NA NA  0.06/ 
0.05 
0.59  NA NA  NA NA  0.24/ 
0.23 
0.11 
Cheng    
et al.,2007  
NA NA  NA NA  0.13/ 
0.14 
0.04  NA NA  NA NA  0.32/ 
0.30 
0.68  0.06/ 
0.05 
0.98  0.15/ 
0.14 
0.09  0.15/ 
0.16 
0.82  NA NA 
Eeles    
et al.,2008   
0.27 
/0.29 
0.76  0.33/ 
0.33 
0.79  NA NA  NA NA  0.05/ 
0.04 
0.71  NA NA  0.05/ 
0.06 
0.74  NA NA  NA NA  0.26/ 
0.26 
0.86 
Breyer    
et al, 2009 
NA NA  NA NA  NA NA  0.27/ 
0.26 
0.34  0.04/ 
0.03 
0.92  NA NA  NA NA  NA NA  NA NA  NA NA 
Wang    
et al.,2009 
NA NA  0.32/ 
0.32 
0.24  NA NA  0.27/ 
0.24 
0.02  NA NA  0.35/ 
0.32 
0.18  0.06/ 
0.07 
0.24  0.16/ 
0.16 
0.76  0.11/ 
0.12 
0.91  NA NA 
Ballistreri 
et al.,2010 
NA NA  NA NA  NA NA  NA NA  NA NA  NA NA  0/    
0.06 
0.38  NA NA  NA NA  NA NA 
Shui     
et al.,2012 
0.26/ 
0.26 
0.08  NA NA  0.13/ 
0.13 
0.03  NA NA  NA NA  0.30/ 
0.30 
0.06  NA NA  0.16/ 
0.14 
0.55  0.14/ 
0.14 
0.20  0.25 
/0.25 
0.18 
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Table 3. Pooled estimated ORs and 95% CIs for the association of TLR4 SNPs in aggressive PCa risk  
 
  Random effects model  Heterogeneity    Random effects model  Heterogeneity 
 Genetic model OR (95% CI) P  I
2
 P   Genetic model OR (95% CI) P  I
2
 P 
rs2737191 Dominant 0.96 (0.84-1.11) 0.61  50.8% 0.11  rs2149356 Dominant 1.01 (0.89-1.14) 0.90  0% 0.62 
 Recessive 0.86 (0.72-1.03) 0.40  0% 0.40   Recessive 0.91 (0.73-1.12) 0.37  6% 0.37 
 AG vs. AA 1.00 (0.83-1.19) 0.97  65.9% 0.03   GT vs. GG 1.03 (0.91-1.17) 0.63  0% 0.86 
 GG vs. AA 0.84 (0.84-1.08) 0.07  35.7% 0.14   TT vs. GG  0.92 (0.72-1.17) 0.49  16.9% 0.31 
 Additive 0.95 (0.84-1.07) 0.41  30% 0.18   Additive 0.99 (0.90-1.08) 0.83  0% 0.69 
rs1927914 Dominant 0.95 (0.83-1.08) 0.43  0% 0.82  rs4986790 Dominant 0.98 (0.83-1.16) 0.82  12.2% 0.34 
 Recessive 0.88 (0.62-1.24) 0.46  52.9% 0.10   Recessive 1.29 (0.57-2.95) 0.55  0% 0.81 
 AG vs. AA 0.96 (0.84-1.10) 0.53  0 0.86   AG vs. AA 0.98 (0.83-1.16) 0.81  10% 0.35 
 GG vs. AA 0.87 (0.63-1.21) 0.41  44.9% 0.14   GG vs. AA 1.28 (0.56-2.93) 0.59  0% 0.82 
 Additive 0.96 (0.87-1.06) 0.44  1% 0.42   Additive 1.02 (0.88-1.17) 0.83  0% 0.62 
rs10759932 Dominant 0.97 (0.83-1.14) 0.70  19.8% 0.29  rs11536889 Dominant 1.05 (0.91-1.21) 0.48  0% 0.49 
 Recessive 1.33 (0.70-2.54) 0.38  44% 0.15   Recessive 1.25 (0.84-1.86) 0.26  0% 0.94 
 TC vs. TT 0.94 (0.79-1.14) 0.54  35.7% 0.20   AG vs. AA 1.03 (0.89-1.20) 0.66  0% 0.48 
 CC vs. TT  1.31 (0.70-2.46) 0.40  40.9% 0.17   GG vs. AA  1.27 (0.85-1.89) 0.24  0% 0.95 
 Additive 0.96 (0.81-1.13) 0.60  20.5% 0.27   Additive 1.06 (0.94-1.20) 0.32  0% 0.87 
rs1927911 Dominant 0.95 (0.83-1.10) 0.49  0% 0.50  rs7873784 Dominant 0.91 (0.80-1.05) 0.19  0% 0.85 
 Recessive 1.06 (0.67-1.67) 0.80  56.2% 0.08   Recessive 1.03 (0.69-1.52) 0.90  0% 0.56 
 GA vs. GG 0.93 (0.80-1.08) 0.35  0% 0.44   GC vs. GG 0.91 (0.79-1.04) 0.17  0% 0.88 
 AA vs. GG  1.03 (0.67-1.61) 0.88  51.1% 0.11   CC vs. GG  1.00 (0.67-1.48) 0.99  0% 0.55 
 Additive 0.99 (0.84-1.17) 0.92  23.9% 0.24   Additive 0.93 (0.83-1.05) 0.26  0% 0.84 
rs11536879 Dominant 1.17 (0.96-1.41) 0.12  0% 0.93  rs1554973 Dominant 0.98 (0.89-1.08) 0.71  0% 0.69 
 Recessive 0.82 (0.17-3.86) 0.80  0% 0.80   Recessive 1.01 (0.83-1.24) 0.91  0% 0.86 
 AG vs. AA 1.18 (0.97-1.43) 0.10  0% 0.95   TC vs. TT 0.98 (0.88-1.08) 0.67  0% 0.75 
 GG vs. AA  0.83 (0.18-3.91) 0.82  0% 0.45   CC vs. TT  1.01 (0.82-1.23) 0.96  0% 0.83 
 Additive 1.15 (0.95-1.40) 0.15  0% 0.95   Additive 0.99 (0.92-1.07) 0.81  0% 0.95 
 
SNPs that were evaluated by at least 4 studies were shown here. Abbreviation: OR, odds ratio; CI, confidence interval; PCa, prostate cancer 
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Abstract 
Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members expressed on the surface 
of several leukocytes and tissue cells and has a having the key function in detecting pathogen and 
danger-associated molecular patterns. The role of TLR4 in the pathophysiology of several age-related 
diseases is also well recognized, such as prostate cancer (PCa). TLR4 polymorphisms have been related to 
PCa risk, but the relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by 
any systematic reviews.   
 
Methods: We performed a systematic review and meta-analysis of candidate-gene and genome-wide 
association studies analyzing this relationship and included only white populations. Considering 
appropriate criteria, only nine studies were analyzed in the meta-analysis, including 3,937 aggressive PCa 
and 7,382 controls.  
 
Results: Using random effects model, no significant association was found in the ten TLR4 SNPs reported 
by at least four included studies under any inheritance model (rs2737191, rs1927914, rs10759932, 
rs1927911, rs11536879, rs2149356, rs4986790, rs11536889, rs7873784, and rs1554973). Pooled estimates 
from another ten TLR4 SNPs reported by three studies also showed no significant association (rs10759930, 
rs10116253, rs11536869, rs5030717, rs4986791, rs11536897, rs1927906, rs913930, rs1927905, and 
rs7045953). Meta-regression revealed that study type was not a significant source of between-study 
heterogeneity. 
 
Conclusions: TLR4 polymorphisms wereas not significantly associated with the risk of aggressive PCa.  
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Introduction  
Prostate cancer (PCa) is the most common malignancy diagnosed since 1984, the most frequently 
diagnosed cancer, and the second leading cause of cancer-related deaths in 2013 among men in the USA 
[1]. The risk of PCa is related to family history, race, and genetic factors. Several other causes have been 
associated with PCa pathogenesis, including infectious agents, chronic non-infectious inflammatory 
diseases, diet, environmental carcinogens, imbalance of sex hormone, obesity, and urine reflux [2-4]. 
Chronic inflammation has been linked to the pathogenesis of PCa in both epidemiologic studies and 
molecular pathology investigations [5,6]. In particular, several studies have suggested that sexually 
transmitted infections may be a risk factor for PCa through causing inflammation, even though not all the 
studies are consistent [7,8]. Chronic inflammation seems to induce prostate carcinogenesis and also 
promote neoplastic progression [9]. Furthermore, several pathways linking inflammation and PCa have 
been identified: an intrinsic one driven by genetic events that cause neoplasia, and an extrinsic one driven 
by inflammatory conditions that predispose to cancer [9]. Among these, the eicosanoid pathway activated 
by cyclooxygenase 2 (COX-2) has been suggested to be involved in the pathogenesis of aggressive PCa by 
a recent study [10]. COX-2 was over-expressed in PCa tumors and the intensity of immunostaining was 
correlated with prostate tumor grade [11]. Despite the available evidence on the role of the inflammatory 
response in PCa onset and progression, the association between genetic variants of innate immune genes 
and the risk of aggressive PCa remains unclear.  
Toll-like receptor 4 (TLR4) is an important pathogen recognition receptor involved in detection of  
lipopolysaccharide (LPS) of Gram-negative bacteria, and of other exogenous orand endogenous ligands  
[12]. The TLR4 encoding gene is located on chromosome 9q32-q33. Through nuclear factor kappa B 
(NF-κB), TLR4 initiates the production of pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6 
and tumor necrosis factor- (TNF-) [13]. TLR4 also mediates signaling related to tumor cell invasion, 
survival, and metastasis in various cancers [14,15]. Its activity and function seems to be modulated by 
genetic variations, principally single nucleotide polymorphisms (SNPs). Mice with deficiency or mutation 
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of TLR4 had a weaker inflammatory immune response to viral, bacterial [16,17], and protozoal [18] 
infections than that of wild-type mice. Therefore, variations in TLR4 gene may modify the signaling of the 
immune response, which in turn may have effects on the pathogenesis of PCa.  
 Three recent meta-analyses have explored the association between TLR4 SNPs and PCa [19-21]. They 
all reported non-significant findings after stratification by ethnicity. However, these studies focused their 
attention on overall PCa and did not contain genome-wide association studies (GWASs). In addition, they 
did not analyze the association between TLR4 SNPs and the aggressive type of PCa. Thus, we conducted a 
systematic review and meta-analysis of all genetic epidemiologic association studies that have evaluated 
the relationship between TLR4 polymorphisms and risk of aggressive PCa. Both candidate-gene studies and 
GWASs were included. The primary research questions are: (1) is there an association between TLR4 SNPs 
and risk of aggressive PCa and if so, what is the size of the relationship? (2) what is the validity of the 
evidence of association between TLR4 polymorphisms and risk of aggressive PCa?   
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Materials and Methods 
Ethics Statement 
 The execution of each individual study was previously approved by the respective institution. This 
systematic review was performed at the study level without access to individual-level data, and therefore, 
institutional review board approval was not necessary. Informed consent was obtained from each 
participant before the start of each individual study. 
Study Selection 
The study was performed using pre-specified research objectives, search strategy, study eligibility 
criteria, methods of data extraction, and statistical analyses. Relevant studies were identified by searching 
the MEDLINE (http://gateway.ovid.com/), EMBASE (http://www.embase.com), Science Citation Index 
(http://science.thomsonreuters.com/cgi-bin/jrnlst/jlsearch.cgi?PC=K), and Online Mendelian Inheritance in 
Man (http://www.ncbi.nlm.nih.gov/omim) databases for all genetic association studies published before 
February 2013, using combinations of the search terms “toll-like receptor 4,” OR “toll-like receptor 4 
gene,” OR “TLR,” OR “TLR gene,” OR “TLR4,” OR “TLR4 gene,”  AND “prostate cancer,” OR 
“prostatic neoplasms.” GWASs were searched using combinations of the search terms “genome-wide 
association study,” OR “GWAS,” AND “prostate cancer,” OR “prostatic neoplasms.” In addition, we 
manually searched the reference lists from reviews and original articles to retrieve other papers relevant to 
the topic. Where there was overlap in the study populations of published papers, only the largest study was 
included. No language restriction was placed on the literature search strategies. Unpublished findings were 
not identified.  
Exposure Measures 
The main exposure variables were TLR4 genotypes as measured in blood DNA samples from men in 
the respective studies. This meta-analysis summarized TLR4 SNPs which were reported by at least three 
included studies. Because many TLR4 SNPs were explored by two studies only, and the respective sample 
sizes were small, these SNPs were not analyzed in this meta-analysis. 
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Outcome Measures 
The outcome measure was aggressive PCa as defined by Gleason score greater than or equal to seven, 
or TNM stage greater than or equal to T3b or any nodal involvement or any distant metastases. However, 
some included studies extended this definition. Controls for aggressive PCa are ideally men without 
aggressive PCa chosen from the population at risk, although some studies selected controls from men 
without screening for occult PCa (Table 1).   
Data Extraction 
Three of us (PH Weng, YL Huang, and YC Chen) independently reviewed each published paper and 
extracted relevant information examining the associations between TLR4 polymorphisms and risk of 
aggressive PCa. Inter-observer differences, if any existed, were reconciled through group discussion. In 
order to pool data from different studies, we requested data from each study based on the definition for 
aggressive PCa in this meta-analysis, which may be slightly different from their original design. For 
GWASs that did not report detailed information of TLR4, we contacted the investigators to obtain data on 
advanced PCa counts and the corresponding TLR4 genotyping frequencies. To avoid population 
stratification, this meta-analysis was restricted to samples taken from European ancestry. We evaluated 
selection bias based on the extent to which controls are representative of the “person-time population” 
from which the cases were sampled, and the extent to which cases are a random sample of that latter 
population. 
Statistical Analyses 
Meta-analyses were performed for SNPs that were reported by at least three included studies. The 
pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between TLR4 genotypes 
and risk of aggressive PCa were calculated using random effects models. Random effects models are 
preferred to fixed effect models because of the differences in study designs and study populations [22]. To 
incorporate both within-study and between-study variability, we used DerSimonian and Laird’s [23] 
random effects models to pool the estimates of log OR from each individual study (unadjusted for 
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covariates). Between-study heterogeneity was quantified by using the I
2
 statistic [24,25], which indicates 
the proportion of variability across studies attributable to heterogeneity. Tests of heterogeneity were 
assessed by a χ2 statistic. To explore the inheritance mode for the effect of TLR4 polymorphisms, we 
evaluated the following genotype contrasts (where a and A denote minor and major alleles, respectively): 
(1) a/a and A/a combined versus A/A (dominant model); (2) a/a versus A/a and A/A combined (recessive 
model); (3) a/a versus A/A and A/a versus A/A (co-dominant model); (4) the increment of one minor allele 
(additive model). The Hardy-Weinberg equilibrium (HWE) was assessed via  χ2 χ2 test. We did not 
perform haplotype analysis because none of the previous studies performed haplotype analysis specific for 
these SNPs. Because most GWASs did not adjust for covariates, this meta-analysis reported unadjusted 
pooled results.  
 
To evaluate the presence of publication bias, we examined the funnel plot, by plotting the reciprocal of 
the standard error of log OR versus the log OR, for symmetry. The Egger linear regression test was also 
performed to assess funnel plot’s asymmetry [26]. Random effects meta-regression was performed under 
dominant model to explore possible sources of between-study heterogeneity. Study type (candidate-gene 
studies vs. GWASs) was the pre-specified covariate. We did not perform stratification analysis according 
to differences in control and case selection, because such influences are complex and are usually not 
unidirectional. Because previous studies revealed high concordance rate across genotyping platforms [27], 
stratification analysis was not carried out according to this covariate. Analyses were performed with Stata 
version 11.0 software (Stata Corporation, College Station, TX, USA). All P values were two-sided. 
QUANTO program (http://hydra.usc.edu/gxe/) was used to evaluate statistical power of the association 
between TLR4 polymorphisms and aggressive PCa.  
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Results 
Characteristics of Association Studies 
Using the pre-specified search methodology we retrieved forty relevant publications (Figure 1). After 
excluding duplicates (n=10), seventeen studies were further excluded due to the following reasons: (1) not 
European ancestry (n=5), (2) partially overlapped populations (n=9), (3) lack of controls (n=1), and (4) 
GWAS which did not include TLR4 gene (n=2).  
We contacted the authors of the remaining 13 relevant studies for necessary details, and authors for of 
three of the GWASs [28-30] didn’t respond and were thus excluded. One GWAS was excluded because it 
didn’t contain the information of PCa aggressiveness [31]. For studies composed of multiple cohorts (e.g., 
Lindstrom et al. [32] ), we tried to obtain data from each cohort and used the original study to represent 
each cohort (e. g., Chen et al. [33] for HPFS, Dunggan et al. [34] for CAPS, and Yeager et al. for PLCO 
[35] for PLCO). For the CAPS study, the GWAS by Dunggan et al. [34] was selected instead of the 
candidate-gene study done by Zheng et al. [36] because the former was composed of aggressive PCa cases 
from Zheng’s study and evaluated more SNPs. In sum, nine studies were included for the meta-analysis. 
A total of 3,937 aggressive PCa cases and 7,382 controls were included in this work. Six studies were 
candidate-gene studies [33,37-41], and three of them were GWASs [34,35,42]. Six papers studied US 
populations [33,35,37-39], one studied a Swedish population [34], one studied the combination of UK and 
Australian population [42], and one studied an Italian population [40]. Details of the studies analyzed in 
this meta-analysis were summarized in Table 1, including first author, year of publication, type of study, 
ancestry, sample size, control selection, possible sources of selection bias, definition of PCa 
aggressiveness, genotyping methods and quality control. 
For the association between TLR4 SNPs and aggressive PCa, seven studies assessed rs4986790 
[33-35,37,39,40,42]; five studies investigated rs2149356 [33,34,37,39,41], rs11536889 [33,34,37,39,41], 
rs7873784 [33,34,37,39,41]; and four studies explored rs2737191[34,35,41,42] , rs1927914 [33,34,38,39], 
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rs10759932 [33,34,37,41], rs1927911 [33,34,38,39], rs11536879 [34,35,38,42], and rs1554973 
[34,35,41,42].  
Allele Frequencies of TLR4 SNPs 
Ten TLR4 SNPs had been evaluated by at least 4 included studies. The minor allele frequencies (MAF) 
between case and controls were shown in Table 2, along with the test for HWE in controls. Among them, 
three SNPs are located on 5’ untranslated region (UTR, rs2737191, rs1927914 and rs10759932), three are 
intronic SNPs (rs1927911, rs11536879, and rs2149356), one is non-synonymous exonic SNP (rs4986790), 
and three SNPs are located on 3’ UTR (rs11536889 , rs7873784, and rs1554973). Another 10 TLR4 SNPs 
were reported by 3 studies, including one SNP located on the promoter region (rs10759930), one SNP 
located on 5’UTR (rs10116253), two intronic SNPs (rs11536869 and rs5030717), one non-synonymous 
exonic SNP (rs4986791), and five SNPs located on 3’ UTR (rs11536897, rs1927906, rs913930, rs1927905, 
and rs7045953). The locations of the explored SNPs (10 SNPs with ≧4 studies, 10 SNPs with 3 studies) 
are shown in Figure 2. rs2149356, rs4986790 and rs7873784 in Chen’s study and rs1927911 in Wang’s 
study were out of HWE (P = 0.01-0.03) but were kept in the analysis because the HWE tests were not 
significant after correction for multiple tests. 
Meta-Analysies 
Using random effects meta-analysis, the ten TLR4 SNPs (rs2737191, rs1927914, rs10759932, 
rs1927911, rs11536879, rs2149356, rs4986790, rs11536889, rs7873784, and rs1444973) were not 
associated with the risk of aggressive PCa regardless of the inheritance model used (Table 3, Figure 3). The 
meta-analysis was also performed for another ten SNPs which were reported by three included studies 
(rs10759930, rs10116253, rs11536869, rs5030717, rs4986791, rs11536897, rs1927906, rs913930, 
rs1927905, and rs7045953) (Table S1). None of the SNPs revealed significant association with aggressive 
PCa. This meta-analysis was reported according to the PRISMA checklist [43] (Table S2).  
Publication Bias  
Funnel plots were used to assess the relationship between the ten TLR4 SNPs and aggressive PCa 
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(Figure S1). Using the Egger linear regression test, possible publication bias was found among the 
included studies on rs1554973 (Egger test P = 0.06). For the other 9 SNPs, P values ranged from 0.2 to 
0.77.  
Meta-regression 
Random effects meta-regression was performed under dominant model. Different study type 
(candidate-gene studies vs. GWASs) was not a significant source of between-study heterogeneity (P value 
ranged from 0.15 to 0.79 for the ten TLR4 SNPs). 
Power Calculation 
For people of European ancestry, given a MAF of 0.15 and α of 0.05, this study had over 95% power 
to detect an OR of 1.20 for 3,937 cases and 7,382 controls.  
 Formatted: Indent: First line:  0 ch
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Discussion 
Recently, some researchers hypothesized that PCa is the result of a chronic inflammatory process [44]. 
Proliferative inflammatory atrophy (PIA), proposed as a potential precursor to PCa, occurs frequently in 
the periphery of the prostate gland where PCa occurs [5]. PIA lesions seem to be the result of different 
conditions, including infections, chronic non-infectious inflammatory diseases, dietary carcinogens, 
physical trauma, imbalance of sex hormone and urine reflux [9].Chronic infections may contribute to PIA 
and lead to onset of PCa [45-47]. Several innate inflammatory pathways seem to be involved. Among these, 
TLR4 pathway plays a crucial role [48].  
TLR4 recognizes pathogen-associated molecular patterns, i.e. LPS [46]. Damage-associated molecular 
pattern molecules may also interact with TLR4, i.e. oxidized low-density lipoprotein (LDL) [49], one of 
the atherogenic lipoproteins associated with atherosclerosis [50] and insulin resistance [51,52]. Their 
interaction leads to the initiation of inflammatory response via NF-κB (Figure 4) [53]. TLR4 can also 
promote PCa development through releasing inflammatory mediators. Associations between TLR4 SNPs 
and PCa have been examined in several studies, though discordant data have been reported. However, the 
relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by any systematic 
reviews. Thus, we performed a systematic review and meta-analysis of candidate-gene studies and GWASs 
analyzing this relationship and restricted to samples taken from European ancestry.  
In the current meta-analysis, none of the examined TLR4 SNPs was significantly associated with risk of 
aggressive PCa under any inheritance model. No significant association was found between the TLR4 
SNPs (5’UTR: rs2737191, rs1927914 and rs10759932; intron: rs1927911, rs11536879, and rs2149356; 
exon: rs4986790; 3’UTR: rs11536889, rs7873784, and rs1554973) and risk of aggressive PCa in the 
pooled analysis. The non-significant findings may be attributable to (1) failure to adjust for the 
conventional risk factors of PCa, e.g. family history of PCa, (2) inability to assess the within-population 
heterogeneity or geographic variation, and (3) the studied TLR4 SNPs may be more closely related to 
non-aggressive PCa.  
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 Three recent meta-analyses evaluated the association between TLR4 SNPs and overall PCa. Jing et al. 
[19], including four candidate-gene studies [33,37,39,40], examined two TLR4 SNPs (rs4986790 and 
rs4986791) and found that rs4986790 showed a protective effect on overall PCa under co-dominant and 
recessive models. However, the effect was not statistically significant after stratification by ethnicity. 
Another work by Zhang et al. [20] examined six TLR4 SNPs (rs1927914, rs4986790, rs4986791, 
rs11536889, rs1927911, rs2149356) and did not find significant associations with overall PCa. The pooled 
estimates of Zhang et al. were derived from one Asian study [54] and four other populations of European 
ancestry [33,36,39,41], which might be confounded by population stratification. Zhu et al. [21] examined 
rs4986790 and rs4986791 and found no significant association with overall PCa in five populations of 
European ancestry [33,36,37,39,40]. In summary, our findings on aggressive PCa are consistent with the 
previous meta-analyses on overall PCa. Our study had several advantages over the previous meta-analyses: 
(1) this study additionally included GWASs, whereas previous meta-analyses included candidate-gene 
studies only [19-21] , (2) this study focused on aggressive PCa, which is more clinically relevant, (3) this 
study was restricted to populations of European ancestry to avoid population stratification, and (4) this 
study evaluated an additional 14 SNPs, which were not reported in the previous meta-analyses. 
 Previous candidate-gene studies and GWASs found inconsistent results for the association between 
TLR4 polymorphisms and PCa risk. This may be explained by different ethnicity, within-population 
heterogeneity, case and control selection, gene-gene interactions, and gene-environment interactions. 
Although most of the relevant medical centers were in the “catchment” area, Cheng and colleagues [37] 
used controls from medical centers, which differ from the source population in that not all men with 
potential PCa would go to these centers to be screened and diagnosed. 
 There were some limitations of this study. One of them is the possibility of publication bias. Though 
the funnel plots did not reveal obvious publication bias among most of TLR4 SNPs, the SNPs reported in 
this study were under the influence of publication bias because only SNPs explored in ≧3 studies were 
included. We were unable to include three other GWASs because the authors did not respond to our data 
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request [28-30]. After exclusion of men with African and Asian ancestry, there was little evidence that 
population stratification was a cause of confounding. Though the included studies were conducted 
separately in the United States, Sweden, Italy, UK and Australia, a prior theoretical calculation on genetic 
case-control studies showed that ignoring ethnicity among non-Hispanic U.S. Caucasians with ancestries 
from different European countries resulted in bias of less than 1% [55]. Last, the included studies used 
different genotyping approaches, which may be associated with different genotyping success rates and data 
quality. However, genotyping errors are expected to be small, and thus the resulting biases are likely to be 
small.  
 This study had some advantages. To the best of our knowledge, this is the first meta-analysis on TLR4 
polymorphisms and aggressive PCa, which shows more clinical relevance. All the included studies were 
reasonably well-designed epidemiological studies. Genotyping was carried out “blind” to the disease status, 
and assessment of aggressive PCa was carried out “blind” to the genotypes. This study had sufficient 
power (> 0.95) to detect a potential OR of aggressive PCa associated with a SNP of 1.20. This study 
presents the best available evidence we have available on the relationship between TLR4 polymorphisms 
and risk of aggressive PCa. 
 In conclusion, this study found that none of the examined TLR4 SNPs were significantly associated 
with risk of aggressive PCa under any mode of inheritance. Control selection, different ancestry, small 
statistical power in some studies, publication bias, gene-gene and gene-environment interactions, different 
genotyping approaches, and issues of multiple tests may contribute to the inconsistent findings in previous 
studies. Meta-regression revealed that different study type (candidate-gene studies vs. GWASs) was not a 
significant source of between-study heterogeneity. Large-scale and well-designed studies using 
population-based controls and more studies in each ethnic group are needed to confirm our findings. 
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Figure legends 
 
Figure 1. Study selection flowchart 
Forty studies were reviewed after literature search. Among them, 31 studies were excluded due to 
duplication, race other than whites, and insufficient data. A total of 9 studies were included for 
meta-analysis. 
 
Figure 2. TLR4 SNPs evaluated in this meta-analysis 
This plot was generated by the Locusview program. The highlighted boxed SNPs were TLR4 
polymorphisms explored by at least four studies. The remaining SNPs were those reported by had at least 
three studies that were , discussed in the supplemental data. 
 
Figure 3. Forest plot examines relationship between TLR4 SNPs and risk of aggressive prostate 
cancer 
Odds ratios and weights were demonstrated for each individual study and for the pooled analysis, assuming 
a dominant model. SNPs that were evaluated by at least 4 studies were shown here. 
 
Figure 4. The role of TLR4 in innate immunity 
TLR4 receptors are responsible for the recognition of bacterial lipopolysaccharide (LPS) monomers and 
partially oxidized LDL (oLDL) on innate immune cells. LPS monomers and oLDL bind to sites on the 
protein, CD14. CD14 promotes the binding of these ligands to the TLR4-MD-2 complex, which signals the 
activation of the nuclear factor kappa B (NF-B) pathway. NF-B products enter the nucleus and results in 
transcription followed by the production of cytokines, and the activation of multiple inflammatory 
pathways. This figure was adapted from DeFranco et al. [48]. 
 
 
 
 
 
 
 21 
 
Table 1. Characteristics of the study populations that evaluated the relationship between TLR4 polymorphisms and risk of prostate 
cancer  
 
Source,  
publication year 
(study year) 
Type of 
study 
Country/ 
ancestry 
Aggressive 
PCa/ 
control 
Control selection Comments about  
control 
selection 
Case selection Definition of 
aggressive 
prostate cancer  
Outcome 
assessment 
“blinded” to 
genotype 
Genotyping procedures Genotyping 
quality control 
Chen et al., 2005 
 
(1993-1995) 
 
Candidate 
gene 
U.S. / 
97% 
Caucasians 
 
260/ 
700 
Age- matched controls 
from prospective 
cohort 
PSA tested in controls  Incident PCa TNM stage T3b 
or T4 or N1 or 
M1 or death due 
to PCa or 
Gleason sum  7 
Yes MassARRAY system 
(SEQUENOM)** 
100% 
concordance,  
> 95% 
genotyping 
success 
Dunggan et al., 
2007 
 
(2001-2002) 
  
 
GWAS Sweden/ 
Not mentioned 
505/ 
507 
Age-matched 
population controls 
from the same 
geographical region 
74% response rate in 
cases, 52% in controls. 
No PSA tested in 
controls.  
PCa from 
cancer registry 
TNM stage T3 or 
T4 or N+ or M+ 
or grade III or 
Gleason sum > 7 
or PSA > 100 
ng/ml 
Yes MassARRAY system 
(SEQUENOM) ** 
>99 % 
concordance, 
>98% genotyping 
success 
Yeager et al., 2007  
 
(1993-2001) 
GWAS U.S. 
/White and 
non-hispanic 
1081/ 
1416 
Risk set sampling from 
a population-based 
randomized controlled 
trial 
PSA tested in controls  Incident PCa Gleason sum  7 
or stage  3 
Yes Illumina system  >99 % 
concordance, 
>99% 
genotyping 
success 
Cheng et al., 2007 
 
(2002-2004) 
Candidate 
gene 
U.S./ 
Caucasians  
417/ 
417 
From annual medical 
examinations at the 
same medical 
institutions of cases 
Hospital-based study. 
PSA tested in controls  
Incident PCa TNM stage  
T2c or Gleason 
sum  7 or PSA> 
10 ng/ml 
Yes Taqman  100% 
concordance, 
99.9% 
genotyping 
success 
Eeles et al., 2008 
 
(1993-2001) 
  
GWAS U.K., 
Australia/ 
Excluded self- 
reported 
“non-white” 
564/ 
1894 
Community-based 
randomized controlled 
trial/electoral rolls  
Controls to be 
frequency matched to 
the geographical 
distribution of the 
cases.  
PCa from 
cancer registry, 
urology clinic 
Gleason sum  7 Yes Stage 1: Illumina Infinium 
HumanHap550 array 
Stage 2: Taqman 
>97 % SNPs at 
a confidence 
score of  0.25, 
98.8 % 
concordance  
Breyer et al.,2009 
 
(2002-2008) 
Candidate- 
gene 
U.S./ 
Americans of 
Northern 
European 
decents 
441/ 
772 
Age-matched controls 
from a preventive 
screening 
Hospital-based. 
PSA tested in controls  
Incident PCa Gleason sum  7 Yes Illumina GoldenGate platform 
and Taqman 
99.7 % of 
genotyping 
success 
Wang et al., 2009 
 
(1992-2002) 
Candidate 
gene 
U.S./ 
White only 
77/ 
264 
Age- matched controls 
from a prospective 
cohort  
No PSA tested in 
controls   
Incident PCa TNM stage T3 or 
T4 or N1 or M1 
or death due to 
PCa or Gleason 
sum  7 
Not  
mentioned 
Taqman 93-99 % 
genotyping 
success 
Ballistreri et al., Candidate Italy/ 32/ Age-matched controls Hospital-based study.  Prevalent PCa Gleason sum  7 Yes RFLP-PCR Not mentioned 
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2010 
 
(NA) 
gene European 
ancestry 
125 in good health No clear description 
on control selection. 
No PSA tested in 
controls 
Shui et al., 2012 
 
(1982-2004) 
Candidate 
gene  
U.S./ White 560/ 
1287 
Risk set sampling from 
a prospective cohort, 
matched on age and 
smoking 
 
No PSA tested in 
controls 
Incident PCa TNM stage T3 or 
T4, M1 or N1 or 
death due to PCa 
or Gleason sum 
 7 
Yes Sequenom iPLEX 
matrix-assisted laser 
desorption/ionization time of 
flight (MALDI-TOF) mass 
spectrometry technology. 
100% 
concordance, 
 >95% 
genotyping 
success 
Abbreviations: PCa, prostate cancer; TNM, the tumor node metastases classification system; PSA, prostate specific antigen; GWAS, 
genome-wide association study; RLFP-PCR, restriction fragment length polymorphism-polymerase chain reaction 
All studies met the following criteria and they were not listed in the table: (1) clear description of laboratory methods, (2) genotyping identical 
for cases and controls, (3) genotyping blinded to case control status, and (4) specimen came from peripheral blood sample. 
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Table 2. Characteristics of included studies 
 
 
SNPs that were evaluated by at least 4 studies were shown here. Abbreviations: MAF, minor allele frequency; HWE, Hardy–Weinberg 
equilibrium; NA, not available. 
 
 
 
 rs2737191 
(A/G) 
 rs1927914 
(A/G) 
 rs10759932 
(T/C) 
 rs1927911 
(G/A) 
 rs11536879 
(A/G) 
 rs2149356 
(G/T) 
 rs4986790 
(A/G) 
 rs11536889 
(A/G) 
 rs7873784 
(G/C) 
 rs1554973 
(T/C) 
 MAF    
case/  
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
 MAF 
case/ 
control 
HWE P 
in 
controls 
Chen     
et al.,2005 
NA NA  0.30/    
0.35 
0.15  0.14/ 
0.16 
0.09  0.25/ 
0.29 
0.43  NA NA  0.30/ 
0.34 
0.02  0.04/ 
0.05 
0.01  0.15/ 
0.14 
0.52  0.15/ 
0.18 
0.03  NA NA 
Dunggan  
et al.,2007 
0.27/ 
0.27 
0.46  0.33/  
0.34 
0.55  0.16/ 
0.15 
0.71  0.27/ 
0.26 
0.74  0.01/ 
0.01 
0.82  0.31/ 
0.32 
0.89  0.05/ 
0.06 
0.15  NA NA  0.11/ 
0.13 
0.99  0.19/ 
0.21 
0.45 
Yeager   
et al.,2007  
0.28/ 
0.29 
0.88  0.32/ 
0.32 
0.94  NA NA  NA NA  0.04/ 
0.04 
0.83  NA NA  0.06/ 
0.05 
0.59  NA NA  NA NA  0.24/ 
0.23 
0.11 
Cheng    
et al.,2007  
NA NA  NA NA  0.13/ 
0.14 
0.04  NA NA  NA NA  0.32/ 
0.30 
0.68  0.06/ 
0.05 
0.98  0.15/ 
0.14 
0.09  0.15/ 
0.16 
0.82  NA NA 
Eeles    
et al.,2008   
0.27 
/0.29 
0.76  0.33/ 
0.33 
0.79  NA NA  NA NA  0.05/ 
0.04 
0.71  NA NA  0.05/ 
0.06 
0.74  NA NA  NA NA  0.26/ 
0.26 
0.86 
Breyer    
et al, 2009 
NA NA  NA NA  NA NA  0.27/ 
0.26 
0.34  0.04/ 
0.03 
0.92  NA NA  NA NA  NA NA  NA NA  NA NA 
Wang    
et al.,2009 
NA NA  0.32/ 
0.32 
0.24  NA NA  0.27/ 
0.24 
0.02  NA NA  0.35/ 
0.32 
0.18  0.06/ 
0.07 
0.24  0.16/ 
0.16 
0.76  0.11/ 
0.12 
0.91  NA NA 
Ballistreri 
et al.,2010 
NA NA  NA NA  NA NA  NA NA  NA NA  NA NA  0/    
0.06 
0.38  NA NA  NA NA  NA NA 
Shui     
et al.,2012 
0.26/ 
0.26 
0.08  NA NA  0.13/ 
0.13 
0.03  NA NA  NA NA  0.30/ 
0.30 
0.06  NA NA  0.16/ 
0.14 
0.55  0.14/ 
0.14 
0.20  0.25 
/0.25 
0.18 
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Table 3. Pooled estimated ORs and 95% CIs for the association of TLR4 SNPs in aggressive PCa risk  
 
  Random effects model  Heterogeneity    Random effects model  Heterogeneity 
 Genetic model OR (95% CI) P  I
2
 P   Genetic model OR (95% CI) P  I
2
 P 
rs2737191 Dominant 0.96 (0.84-1.11) 0.61  50.8% 0.11  rs2149356 Dominant 1.01 (0.89-1.14) 0.90  0% 0.62 
 Recessive 0.86 (0.72-1.03) 0.40  0% 0.40   Recessive 0.91 (0.73-1.12) 0.37  6% 0.37 
 AG vs. AA 1.00 (0.83-1.19) 0.97  65.9% 0.03   GT vs. GG 1.03 (0.91-1.17) 0.63  0% 0.86 
 GG vs. AA 0.84 (0.84-1.08) 0.07  35.7% 0.14   TT vs. GG  0.92 (0.72-1.17) 0.49  16.9% 0.31 
 Additive 0.95 (0.84-1.07) 0.41  30% 0.18   Additive 0.99 (0.90-1.08) 0.83  0% 0.69 
rs1927914 Dominant 0.95 (0.83-1.08) 0.43  0% 0.82  rs4986790 Dominant 0.98 (0.83-1.16) 0.82  12.2% 0.34 
 Recessive 0.88 (0.62-1.24) 0.46  52.9% 0.10   Recessive 1.29 (0.57-2.95) 0.55  0% 0.81 
 AG vs. AA 0.96 (0.84-1.10) 0.53  0 0.86   AG vs. AA 0.98 (0.83-1.16) 0.81  10% 0.35 
 GG vs. AA 0.87 (0.63-1.21) 0.41  44.9% 0.14   GG vs. AA 1.28 (0.56-2.93) 0.59  0% 0.82 
 Additive 0.96 (0.87-1.06) 0.44  1% 0.42   Additive 1.02 (0.88-1.17) 0.83  0% 0.62 
rs10759932 Dominant 0.97 (0.83-1.14) 0.70  19.8% 0.29  rs11536889 Dominant 1.05 (0.91-1.21) 0.48  0% 0.49 
 Recessive 1.33 (0.70-2.54) 0.38  44% 0.15   Recessive 1.25 (0.84-1.86) 0.26  0% 0.94 
 TC vs. TT 0.94 (0.79-1.14) 0.54  35.7% 0.20   AG vs. AA 1.03 (0.89-1.20) 0.66  0% 0.48 
 CC vs. TT  1.31 (0.70-2.46) 0.40  40.9% 0.17   GG vs. AA  1.27 (0.85-1.89) 0.24  0% 0.95 
 Additive 0.96 (0.81-1.13) 0.60  20.5% 0.27   Additive 1.06 (0.94-1.20) 0.32  0% 0.87 
rs1927911 Dominant 0.95 (0.83-1.10) 0.49  0% 0.50  rs7873784 Dominant 0.91 (0.80-1.05) 0.19  0% 0.85 
 Recessive 1.06 (0.67-1.67) 0.80  56.2% 0.08   Recessive 1.03 (0.69-1.52) 0.90  0% 0.56 
 GA vs. GG 0.93 (0.80-1.08) 0.35  0% 0.44   GC vs. GG 0.91 (0.79-1.04) 0.17  0% 0.88 
 AA vs. GG  1.03 (0.67-1.61) 0.88  51.1% 0.11   CC vs. GG  1.00 (0.67-1.48) 0.99  0% 0.55 
 Additive 0.99 (0.84-1.17) 0.92  23.9% 0.24   Additive 0.93 (0.83-1.05) 0.26  0% 0.84 
rs11536879 Dominant 1.17 (0.96-1.41) 0.12  0% 0.93  rs1554973 Dominant 0.98 (0.89-1.08) 0.71  0% 0.69 
 Recessive 0.82 (0.17-3.86) 0.80  0% 0.80   Recessive 1.01 (0.83-1.24) 0.91  0% 0.86 
 AG vs. AA 1.18 (0.97-1.43) 0.10  0% 0.95   TC vs. TT 0.98 (0.88-1.08) 0.67  0% 0.75 
 GG vs. AA  0.83 (0.18-3.91) 0.82  0% 0.45   CC vs. TT  1.01 (0.82-1.23) 0.96  0% 0.83 
 Additive 1.15 (0.95-1.40) 0.15  0% 0.95   Additive 0.99 (0.92-1.07) 0.81  0% 0.95 
 
SNPs that were evaluated by at least 4 studies were shown here. Abbreviation: OR, odds ratio; CI, confidence interval; PCa, prostate cancer 
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